CDK6在早期卵巢癌组织中的表达及其临床价值评价

摘要

目的 研究CDK6在早期卵巢癌组织中的表达.方法 选取本院2017年1月至2018年5月收治的卵巢癌患者42例为研究对象,并随机在志愿者中选取42例健康女性为对照组,通过PCR以及免疫组化法检测两组对象CDK6的表达情况,并分析实验组患者各临床参数与CDK6表达的相关性.结果 实验组CDK6mRNA表达及CDK6蛋白表达相对于对照组明显上升,实验组CDK6高表达率28.57％(12/42),高于对照组11.90％(5/42),差异有统计学意义(P＜0.05);CDK6表达结果与年龄、病理分类、分化程度、临床分期等参数相关性较低(P=1.113、0.524、0.627、0.068);患者生存时间与CDK6表达时间具有一定相关性,CDK6表达越高,患者生存时间越短.结论 CDK6表达越高,卵巢癌发生概率越大.%Objective To study the expression of CDK6 in early ovarian cancer tissue.Methods Forty-two patients with ovarian cancer treated at our hospital from January,2017 to May,2018 were selected as study objects.And 42 healthy women were randomly selected from the volunteers as a control group.The expression of CDK6 in both groups was detected by PCR and immunohistochemistry.The correlation between clinical parameters and CDK6 expression in the experimental group was analyzed.Results The expressions of CDK6 mRNA and CDK6 protein in the experimental group were significantly higher than those in the control group.The high expression rate of CDK6 in the experimental group was 28.57％,which was much higher than that in the control group (11.90％).The CDK6 expression correlated with age,pathological classification,differentiation degree,clinical stage in low levels (P=1.113,0.524,0.627,and 0.068).The patients' survival time had a certain correlation with the expression time of CDK6.The higher the CDK6 expression,the shorter the patients' survival time.Conclusion The higher the expression of CDK6 is,the greater the incidence of ovarian cancer.